Australia Health

Island Pharmaceuticals (ASX:ILA) commenced manufacturing of its active pharmaceutical ingredient, Galidesivir, on Oct. 1.

TruScreen Group (ASX:TRU) announced that CEO Martin Dillon has resigned from his position for personal reasons, effective Oct. 31.

Optiscan Imaging (ASX:OIL) has lodged a 510(k) submission with the U.S. Food and Drug Administration for its InForm digital pathology device.

Syntara (ASX:SNT) has expanded its double-blind, placebo-controlled Phase 1b clinical study of its topical drug SNT-9465.

Talius Group (ASX:TAL) has entered into a binding commercial partnership with Health Generation to take its co-branded CareGen Intelligence platform to market.

LTR Pharma (ASX:LTP) completed its final Phase 2 clinical report, confirming that its nasal spray achieved peak blood concentration in 10 minutes.

Imagion Biosystems (ASX:IBX) has secured central Institutional Review Board ethics approval from Advarra for its Phase 1b/2 clinical trial.

Telix Pharmaceuticals (ASX:TLX) announced that the U.S. Food and Drug Administration granted a Fast Track designation for its BiPASS prostate cancer imaging programme.

Neuren Pharmaceuticals (ASX:NEU) announced partner Acadia Pharmaceuticals (NASDAQ:ACAD) secured a US patent allowance extending trofinetide protections.

Memphasys (ASX:MEM) has executed a convertible note subscription agreement with Peters Investments to secure a $3.5 million.

Firebrick Pharma (ASX:FRE) has approved a comprehensive strategic plan to enter the US retail pharmacy market with its Nasodine product range.

Argent BioPharma (ASX:RGT) has executed an exclusive licence agreement with NLC to commercialise its Tollovir, Tollovid, and NutraVir antiviral applications globally outside of China.